Akzo Nobel Earnings Call: Cost Cuts, Cash and Caution

Akzo Nobel ((AKZOY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Akzo Nobel Balances Cost-Led Progress With Market Headwinds in Latest Earnings Call

Akzo Nobel’s latest earnings call struck a cautiously upbeat tone: management highlighted solid operational execution, stronger margins, healthy cash generation and a rich India divestment, even as demand remained soft and currencies weighed on reported figures. The message to investors was that self-help, disciplined capital allocation and a transformational Axalta merger plan are doing the heavy lifting while the company waits for a hesitant coatings market to turn.

Full-Year Profitability Strengthens Despite Soft Demand

Akzo Nobel reported full-year adjusted EBITDA of €1,444 million on a constant-currency, India-adjusted basis, landing within about 1% of its guidance. The adjusted EBITDA margin improved to 14.2%, up 40 basis points from the previous year, signaling that the company is managing pricing, mix and costs more effectively than underlying volumes might suggest. This margin expansion, achieved in a flat-to-soft demand environment, underpins management’s argument that the business is structurally more resilient than in past cycles.

Q4 Delivers Solid EBITDA Growth and Margin Expansion

The fourth quarter underscored that profitability momentum is building. Adjusted EBITDA reached €309 million, or €343 million at constant currencies and adjusted for India, representing roughly 7% growth year-on-year. Q4 margins rose to around 13%, an improvement of 70 basis points versus the prior year quarter. While foreign exchange masked some of the improvement, the underlying trend was one of better cost control and pricing discipline, providing a template for further gains if volumes stabilize.

Strong Free Cash Flow Fuels Deleveraging

Cash generation was a key highlight. Akzo Nobel produced €606 million of free cash flow for the full year, with an especially strong Q4 contribution of €362 million. This enabled the company to reduce net debt below €3 billion and bring leverage down to roughly 2x, in line with its midterm target. For equity investors, the lower leverage ratio reduces financial risk and gives the company more strategic flexibility as it pursues cost programs and the proposed Axalta merger.

High-Multiple India Exit Unlocks Value

The sale of Akzo Nobel India Limited was presented as a value-creating portfolio move. The company secured about €900 million at an attractive multiple of roughly 25 times EBITDA, signaling strong market confidence in the asset. Akzo Nobel also retained its powder coatings business via a minority buyout and locked in a recurring royalty stream from the divested liquid coatings operations. This structure allows the group to monetize value upfront while still participating in the ongoing growth of the Indian coatings market.

SG&A and Industrial Excellence Programs Beat Expectations

Management emphasized that the cost-savings engine is running ahead of plan. The SG&A efficiency program has delivered €200 million in gross cost savings, with €145 million realized so far, and resulted in the elimination of around 2,900 functional roles. This performance exceeds initial targets by roughly €80 million. In parallel, the Industrial Excellence program is on track, with 12 site closures completed and total expected gross savings of €300 million, including a €90 million benefit earmarked for 2026. Together, these initiatives are reshaping the cost base and underpin future margin ambitions.

Half-Billion Euro Cost Takeout Underpins 2026 EBITDA Ambition

Akzo Nobel’s self-help measures add up to roughly €0.5 billion of gross cost savings across SG&A and industrial operations. On the back of these actions, the company is targeting at least €100 million of additional full-year adjusted EBITDA in 2026 on a comparable basis. Management made clear that this uplift is primarily cost-driven rather than volume-led, reflecting a pragmatic view of the demand environment. For investors, the message is that earnings growth will come from internal levers even if the macro backdrop stays sluggish.

Working Capital Discipline and ROI Incrementally Improve

Operational efficiency also showed up in the balance sheet. Trade working capital improved to 14.7% of sales, a 1 percentage point reduction year-on-year, even with some strategic inventory prebuys. Days inventory outstanding were kept flat, signaling better supply chain management. Return on investment nudged up to 13.5% from 13.3%, small but positive progress that supports the claim that capital is being deployed more efficiently as the company streamlines its footprint and cost base.

Axalta Merger Targets Large Synergies and Strategic Scale

A central strategic development is the proposed merger of equals with Axalta. Regulatory filings are underway, and Akzo Nobel is targeting closing in late 2026 or early 2027. Management outlined expectations for at least $600 million of cost synergies, plus additional revenue synergies of 100–200 basis points. The transaction would significantly scale the combined coatings platform, expand geographic and segment exposure and deepen the industrial footprint. While timing and approvals remain uncertain, the potential value creation from synergies is a major plank of Akzo’s medium-term equity story.

Volumes Decline as End Markets Stay Soft

Despite the profitability progress, volumes remain under pressure. Q4 volumes were down 2% year-on-year, driving a 1% decline in organic sales, with price/mix only partly compensating via a 1% increase. Management signaled that it expects a weak first half of 2026 and no meaningful market recovery across the full year, indicating that demand headwinds are structural rather than transient. This cautious view underscores why the company is leaning heavily on cost savings, productivity and portfolio actions to protect earnings.

FX and Portfolio Changes Weigh on Reported Revenue

Reported full-year revenue declined 9%, with only a modest 1% organic drop but a 1% impact from the India divestment and a sizable 6% drag from foreign exchange translation. Management indicated that currency headwinds are not over: it expects a further FX drag of roughly €35 million on 2026 earnings and flagged an estimated €30 million FX headwind in Q1 versus the prior year. For investors, this means that underlying operational improvements may be partially obscured in reported numbers as currency cycles play out.

Coatings Segment Hit by Regional Weakness and Mix

The Coatings segment felt the pinch of regional softness and adverse mix. Q4 coatings volumes were down 3%, particularly hurt by weakness in North America. Negative mix effects, with softer demand in higher-margin subsegments, limited how much profitability could improve despite cost actions and pricing. Management’s commentary suggested that while the core franchise remains sound, the segment’s earnings power is closely tied to a recovery in key industrial and construction-driven markets.

Packaging Business Faces Temporary Disruption

Akzo Nobel’s packaging business is navigating a short-term setback. An industry-wide technology shift and delays in regulatory approvals for a new product have caused a pullback and are expected to lead to market share erosion in 2026. Management framed this as a temporary issue, with recovery anticipated in 2027 once approvals are in place and the new technology is fully deployed. However, this will be a drag on segment performance in the near term and is an area to watch for signs of execution and customer recapture.

Refinish and Powder Coatings Struggle in Key Markets

Automotive refinish remains at trough levels in North America, weighed down by insurance and repair dynamics that limit shop throughput and demand for coatings. Meanwhile, powder coatings have been impacted by weak architectural activity in several regions. The company expects stabilization later in 2026, but near-term conditions remain challenging. These segments are structurally attractive over the long term, but current market softness constrains their ability to contribute meaningfully to earnings growth in the immediate future.

India Divestment Reduces 2026 EBITDA Scope

While financially attractive, the India sale also removes earnings from the 2026 base. Management quantified a scope adjustment that will reduce reported adjusted EBITDA by €40 million in 2026, with €6 million already reflected in December 2025, for a total correction of €46 million. The company is therefore guiding and presenting its 2026 targets on a comparable basis to help investors distinguish between structural profit growth and the mechanical impact of portfolio reshaping.

Suspended Buyback Alters Near-Term Capital Returns

Following the Axalta merger announcement, Akzo Nobel suspended its share repurchase program, including a previously planned €400 million buyback. This alters the near-term shareholder return profile, shifting the focus away from immediate buybacks toward funding strategic initiatives and merger-related priorities. Management signaled that alternative forms of cash return are contemplated as part of the broader merger plan, but concrete details will depend on deal progress, leverage levels and regulatory milestones.

China and Other Regions Add to Demand Uncertainty

Regional dynamics remain a concern, particularly in Asia and North America. The decorative market in China is weak, with management characterizing it as declining in the mid-single digits in 2025 and not expecting a recovery until 2027. Parts of Southeast Asia and North America are also seen as soft in the first half of 2026. This patchy geographic picture reinforces Akzo Nobel’s conservative volume outlook and increases the importance of cost programs and mix management to sustain profitability.

2026 Guidance: Cost-Driven Earnings Growth in a Flat Volume World

For 2026, Akzo Nobel guided to at least a €100 million increase in full-year adjusted EBITDA on a comparable basis, implying reported adjusted EBITDA at or above €1.47 billion after absorbing a €40 million scope impact from the India divestment and about €35 million of FX headwinds. Volumes are expected to be broadly flat, with Q1 resembling Q4 and an additional circa €30 million FX drag in the first quarter. The earnings step-up is heavily anchored in cost actions: the Industrial Excellence program is slated to deliver around €90 million of net savings in 2026 (with €110 million carryover in 2027 and €300 million gross overall), while the SG&A program reaches €200 million of gross savings in total, with at least €50 million carrying into 2026 from roughly 2,900 role eliminations. Pricing is expected to remain positive after a 1% price/mix gain in 2025, and working capital is targeted around or slightly below 14.5%, moving toward a 13–14% midterm goal.

In summary, Akzo Nobel’s earnings call outlined a story of disciplined execution and cost-led progress in the face of persistent demand and currency headwinds. Margin expansion, strong free cash flow, a high-value India exit and a robust cost-reduction pipeline are offsetting weak volumes and regional soft spots, while the proposed Axalta merger offers a potential step-change in scale and synergy benefits. For investors, the company presents a cautious but constructive outlook: earnings growth in the near term will be driven more by what Akzo Nobel can control internally than by a cyclical upturn, with substantial upside possible if end markets eventually recover in line with management’s longer-term expectations.